Posts

Panag Pharma Announces Licensing Agreement With Tetra Bio Pharma

/in /by

Panag Pharma announces licensing agreement with Tetra Bio Pharma

Halifax, Nova Scotia. Panag Pharma Inc. announces that it has entered into a licensing agreement with Tetra Bio Pharma for its Topical ARx and Ocular products.

The Licensing Agreement provides for the continued development and commercialization of Panag’s unique products focused on providing patients with effective relief from pain.

Dr. Cheliak, Panag’s CEO notes that “combining the technical and clinical expertise of Panag with the regulatory and commercialization expertise of Tetra will accelerate the delivery of a new class of pain relief products to patients”.

“We are very pleased to announce this partnership with Panag as we work towards building an innovative product pipeline focused on cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma.

About Panag Pharma:

Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds.

About Tetra Bio-Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.TetraBioPharma.com.

Panag Pharma Announces Launch Of A Regional Pilot Program

/in /by

Halifax, Nova Scotia. Panag Pharma hosted a seminar for Health Care Professionals and the launch of a Regional Pilot Program to introduce Topical AOTC, a new generation pain and inflammation product.

Topical AOTC is a Health Canada approved natural product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Learn more about Topical AOTC

Clinical pain specialists, physiotherapists, chiropractors, sports medicine experts and podiatrists attended the information session. The pilot program will be running until March 17th 2017. During this time, Topical AOTC will be evaluated by a wide range of patients who will work closely with their health care provider. Following completion of the Regional Pilot program, Topical AOTC will be made available to patients through specialty clinics and via direct orders from Panag.

About Panag Pharma Inc.

Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…

Panag Pharma Announces Health Canada License For Topical A OTC (NPN 80070485)

/in /by

Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis.

Topical AOTC uses a novel technology targeting the endocannabinoid system and TRPV1 receptors, both known to play a key role in modulation of pain. There is no other similar product on the market. Panag Pharma will move forward with a regional launch of Topical AOTC to selected clinics in early 2017. Learn more about Topical AOTC

About Panag Pharma Inc.

Panag Pharma is a Halifax, Nova Scotia based Life Sciences company developing a range of products which provide relief from chronic pain and inflammation, especially in sensitive sites, using proprietary plant-derived compounds. Learn more…